Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful ...

After trailing broader equities over the past few years, will the healthcare sector finally bounce back in 2026? It's hard to ...

Migraines. Those who do not have them will never truly understand them. The pain. The fog. The effects they can cause, the way they steal hours, sometimes days, from a life. For Gabrielle Mazzaro, ...

Two leading medical stocks that appear reasonable at current levels are AbbVie (NYSE: ABBV) and Merck (NYSE: MRK). The former ...

Dividend investing rewards patience. The best dividend stocks don’t just pay consistently—they raise payouts year after year, ...

AbbVie (NYSE: ABBV) has the highest share price of any stock on this list, at more than $200 each. But don't let the price ...

Lastly, AbbVie is a fantastic income stock. The company is part of the group of Dividend Kings, corporations that have ...

ASH Annual Meeting and Exposition leaves the oncology community buzzing over a series of late-breaking presentations that experts are calling 'unprecedented.' Major pharmaceutical developers such as ...

“We sit in the low 60s in terms of Botox share, and that's a clear leadership position by a large margin in the U.S.,” AbbVie ...

Mark Manfredi brings over two decades of international biopharmaceutical industry leadership and cancer drug discovery success to DISCOFinancing ...

Discover why AbbVie (ABBV) is rated Strong Buy, with robust 2025 growth, diversified revenues, and attractive valuation.

AbbVie Inc. (NYSE: ABBV) garnered a ‘Buy’ rating from analyst Rajesh Kumar at HSBC, suggesting a robust upside potential for investors. The analyst set a price target of $265, indicating a notable ...